Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

[1]  V. Valero,et al.  Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system , 2012, International journal of cancer.

[2]  V. Valero,et al.  Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells , 2011, International journal of cancer.

[3]  W. Woodward,et al.  Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. , 2011, European Journal of Cancer.

[4]  J. Bennett,et al.  Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Liu,et al.  Effects of an mTOR inhibitor RAD001 on human breast cancer stem cells in vitro and in vivo. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Giovanna Bises,et al.  Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients , 2011, Acta oncologica.

[7]  R. Kimmig,et al.  Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy , 2011, International Journal of Gynecologic Cancer.

[8]  Giuseppe Naso,et al.  Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients , 2011, Breast Cancer Research and Treatment.

[9]  Jingjing Liu,et al.  Abstract PD02-09: Effects of an mTOR Inhibitor RAD001 on Human Breast Cancer Stem Cells In Vitro , 2010 .

[10]  T. Delozier,et al.  Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). , 2010 .

[11]  M. Beckmann,et al.  Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients , 2010 .

[12]  R. Fodde,et al.  Cancer stemness and metastasis: therapeutic consequences and perspectives. , 2010, European journal of cancer.

[13]  T. Gage,et al.  What goes around, comes around: a review of circulating tumor cells. , 2010, MLO: medical laboratory observer.

[14]  G. Kallergi,et al.  Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. , 2010, Cancer letters.

[15]  A. Vincent-Salomon,et al.  Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[17]  J. D'haese,et al.  Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. , 2009, Gastroenterology.

[18]  T. Fehm,et al.  Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells , 2009, Breast Cancer Research.

[19]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[20]  S. Agelaki,et al.  Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer , 2009, British Journal of Cancer.

[21]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[22]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[23]  D. Mavroudis,et al.  Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[25]  R C Coombes,et al.  Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment , 2008, British Journal of Cancer.

[26]  Sabine Kasimir-Bauer,et al.  Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies , 2009, Breast Cancer Research and Treatment.

[27]  D. Mavroudis,et al.  Micrometastatic disease in breast cancer: clinical implications. , 2008, European journal of cancer.

[28]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[29]  G. Kallergi,et al.  Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients , 2008, Breast Cancer Research.

[30]  O. De Wever,et al.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[31]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[32]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[33]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[34]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[35]  O. Böcher,et al.  The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. , 2007, Anticancer research.

[36]  G. Kallergi,et al.  Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells , 2007, Molecular medicine.

[37]  A. Giuliano,et al.  Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2006, Clinical Cancer Research.

[38]  T. Fehm,et al.  A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.

[39]  D. Mavroudis,et al.  Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  François Vaillant,et al.  Steroid hormone receptor status of mouse mammary stem cells. , 2006, Journal of the National Cancer Institute.

[41]  J. Nesland,et al.  Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.

[42]  P. Dam,et al.  Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.

[43]  E. van Marck,et al.  Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.

[44]  T. Fehm,et al.  Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy , 2006, Breast Cancer Research and Treatment.

[45]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[46]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[47]  Maria Athelogou,et al.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  S. Jader,et al.  Invasive breast carcinoma , 2005 .

[49]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[50]  J. Nesland,et al.  Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.

[51]  G. Dontu,et al.  Breast cancer, stem/progenitor cells and the estrogen receptor , 2004, Trends in Endocrinology & Metabolism.

[52]  M. Ladanyi,et al.  HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. , 2004, American journal of clinical pathology.

[53]  Anne Vincent-Salomon,et al.  Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.

[54]  I. Vlachonikolis,et al.  Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[56]  R. Neumann,et al.  Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[59]  I sabel Mortara,et al.  International Union against Cancer , 1938, Nature.